Greenwich LifeSciences (GLSI) Interest & Investment Income (2021 - 2026)
Greenwich LifeSciences' (GLSI) quarterly Interest & Investment Income came in at $22258.0 in Q4 2025, down 49.35% YoY from $43942.0 in Q4 2024, and down 2.36% on a QoQ basis from $22797.0 in Q3 2025.
Powered by 
Analysis
Greenwich LifeSciences (GLSI) Interest & Investment Income (2021 - 2026) Analysis & Trends
Greenwich LifeSciences (GLSI) has 5 years of Interest & Investment Income data on file, last reported at $22258.0 in Q4 2025.
- Quarterly Interest & Investment Income fell 49.35% year-over-year to $22258.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $89700.0 (down 59.78% YoY) and the FY2025 annual result came in at $89700.0, down 59.78% from the prior year.
- Interest & Investment Income slipped to $22258.0 in Q4 2025, from $22797.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $119453.0 in Q2 2023 to a low of $3568.0 in Q3 2021.
- A 5-year average of $49557.8 and a median of $35588.0 in 2022 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2022 — Interest & Investment Income soared 1694.76% — and 2025, when it tumbled 62.55%.
- Tracing GLSI's Interest & Investment Income over 5 years: stood at $16501.0 in 2021, then soared by 531.3% to $104171.0 in 2022, then retreated by 14.28% to $89294.0 in 2023, then plunged by 50.79% to $43942.0 in 2024, then tumbled by 49.35% to $22258.0 in 2025.
- The last three Interest & Investment Income figures came in at $22258.0 (Q4 2025), $22797.0 (Q3 2025), and $20675.0 (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 67.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 35.58 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 27.90 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Greenwich LifeSciences | 231.59 Mn | 231.59 Mn | - | 68,617.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 68,617.00 |
| Dec 31, 2025 | 22,258.00 |
| Sep 30, 2025 | 22,797.00 |
| Jun 30, 2025 | 20,675.00 |
| Mar 31, 2025 | 23,970.00 |
| Dec 31, 2024 | 43,942.00 |
| Sep 30, 2024 | 60,338.00 |
| Jun 30, 2024 | 54,722.00 |
| Mar 31, 2024 | 64,006.00 |
| Dec 31, 2023 | 89,294.00 |
| Sep 30, 2023 | 111,136.00 |
| Jun 30, 2023 | 119,453.00 |
| Mar 31, 2023 | 116,180.00 |
| Dec 31, 2022 | 104,171.00 |
| Sep 30, 2022 | 64,037.00 |
| Jun 30, 2022 | 27,234.00 |
| Mar 31, 2022 | 19,575.00 |
| Dec 31, 2021 | 16,501.00 |
| Sep 30, 2021 | 3,568.00 |
| Jun 30, 2021 | 3,700.00 |